Zhejiang Hisun Pharmaceutical News

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13 21:24

Zhejiang Hisun Pharmaceutical (600267.SH): Apremilast tablets and posaconazole enteric-coated tablets are expected to win centralized procurement bidding.

Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in a joint procurement...

Zhitong FinanceDec 13 19:08

Zhejiang Hisun Pharmaceutical (600267.SH): Participation in the national pharmaceutical centralized procurement aims to win the bid.

Gelonghui reported on December 13 that Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national centralized pharmaceutical procurement organized by the Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office"). After the opening and evaluation of bids by the Joint Procurement Office, the company's products, Aprepitant tablets and Posaconazole enteric-coated tablets, are proposed to win the bid for this centralized procurement. Aprepitant tablets and Posaconazole enteric-coated tablets have been selected for supply provinces based on the market potential of each province, and the results of the selection will be officially announced after being posted by the Joint Procurement Office.

Gelonghui FinanceDec 13 18:42

Express News | Zhejiang Hisun Pharmaceutical: The company's products Apremilast tablets and Posaconazole enteric-coated tablets are proposed to be awarded national centralized pharmaceutical procurement.

BreakingsDec 13 18:35

Express News | Zhejiang Hisun Pharmaceutical: Subsidiary receives approval numbers for two veterinary drug products.

BreakingsNov 28 17:05

Zhejiang Hisun Pharmaceutical (600267.SH): Meropenem is currently in the first round of centralized procurement period, with not a large sales volume

Gelonghui reported on November 15 that zhejiang hisun pharmaceutical (600267.SH) stated on the interactive platform that meropenem is still in the first round of centralized procurement, and the sales are not large. The company will closely monitor subsequent procurement opportunities; by diversifying its operations, the company has shown good recovery. The entire company is working hard to achieve the performance goals set at the beginning of the year. The company's industrial team continues to improve process levels, and the cost reduction and efficiency enhancement efforts have seen results this year. Substantial progress in industrial capacity recovery is expected to occur starting next year.

Gelonghui FinanceNov 15 16:16

China Approves Hisun Pharma's Two Medications for Dogs

MT NewswiresNov 15 16:00

Haizheng Pharmaceutical: Zhejiang Haizheng Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024

SZSIOct 31 00:00 · Announcements

Zhejiang Haizheng Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024

SZSIOct 31 00:00 · Announcements

Express News | Zhejiang Hisun Pharmaceutical: Net income in the third quarter increased by 109.37% year-on-year.

BreakingsOct 30 23:47

Zhejiang Hisun Pharmaceutical (600267.SH): The net income for the first three quarters was 0.515 billion yuan, a year-on-year increase of 16.49%.

GeLongHui October 30th| Zhejiang Hisun Pharmaceutical (600267.SH) released its third-quarter report, with revenue for the first three quarters at 7.87 billion yuan, a 9.50% decrease year-on-year. Net income was 0.515 billion yuan, a 16.49% year-on-year increase. Non-GAAP net income was 0.346 billion yuan, an 8.80% year-on-year increase, with basic earnings per share of 0.44 yuan.

Gelonghui FinanceOct 30 21:28

Express News | Zhejiang Hisun Pharmaceutical has completed the change of leadership in business registration, with Xiao Weihong appointed as the chairman.

BreakingsOct 24 11:38

Hisun Pharma Unit Gets Regulatory Nod for Cat Vaccine

MT NewswiresOct 23 14:40

Zhejiang Hisun Pharmaceutical (600267.SH) passed the pharmaceutical GMP compliance inspection.

zhejiang hisun pharmaceutical (600267.SH) announced that the company obtained the pharmaceutical GMP certification from the Zhejiang Provincial Food and Drug Administration website...

Zhitong FinanceOct 14 17:31

Hisun Pharmaceutical's Parent Nominates Candidate for Chairman

MT NewswiresOct 2 16:02

Hisun Pharmaceutical to Pay Additional Taxes Worth 18 Million Yuan

MT NewswiresOct 2 15:54

zhejiang hisun pharmaceutical (600267.SH): Received a letter from the controlling shareholder suggesting the nomination of the chairman candidate for the board of directors.

Grain Times September 30th | Zhejiang Hisun Pharmaceutical (600267.SH) announced that it has received a letter from the controlling shareholder Zhejiang Hisun Group Co., Ltd. recommending Xiao Weihong as the candidate for the chairman of the board of directors of Zhejiang Hisun Pharmaceutical Co., Ltd. for the ninth session.

Gelonghui FinanceSep 30 17:03

zhejiang hisun pharmaceutical (600267.SH): total supplementary tax payment of 18.0744 million yuan

Gelonghui September 30th: zhejiang hisun pharmaceutical (600267.SH) announced that, through self-inspection, the company and its subsidiaries need to pay a total of 15.4723 million yuan for corporate income tax, value-added tax, and other related taxes, and need to pay a late fee of 2.6021 million yuan, totaling 18.0744 million yuan. As of the date of this announcement, the company has paid the above-mentioned taxes and late fees as required.

Gelonghui FinanceSep 30 17:00

China Approves Hisun Pharmaceutical's Aspergillosis Tablets

MT NewswiresSep 27 18:10

zhejiang hisun pharmaceutical (600267.SH): Posaconazole enteric-coated tablets obtained pharmaceutical registration certificate

On September 26, Gelonhui reported that Zhejiang Hisun Pharmaceutical (600267.SH) recently received the "Drug Registration Certificate" of Posaconazole Enteric-coated Tablets issued by the National Medical Products Administration. Posaconazole enteric-coated tablets are mainly used in the treatment of invasive aspergillosis in adult patients, suitable for preventing the increase of invasive aspergillus and candida infection risk in patients aged 13 and above due to severe immunodeficiency, such as patients who develop graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT) or patients with prolonged neutropenia caused by chemotherapy in hematologic malignancies.

Gelonghui FinanceSep 26 17:18